These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 10554025

  • 1. Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors.
    Du W, Prendergast GC.
    Cancer Res; 1999 Nov 01; 59(21):5492-6. PubMed ID: 10554025
    [Abstract] [Full Text] [Related]

  • 2. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB, Du W, Donover S, Baker J, Liu AX, Sharp DM, Muller AJ, Prendergast GC.
    Oncogene; 2003 Jun 05; 22(23):3578-88. PubMed ID: 12789266
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM, Hamilton AD.
    Oncogene; 2000 Dec 27; 19(56):6584-93. PubMed ID: 11426643
    [Abstract] [Full Text] [Related]

  • 6. The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells.
    Kim HS, Kim JW, Gang J, Wen J, Koh SS, Koh JS, Chung HH, Song SY.
    Toxicol Appl Pharmacol; 2006 Sep 15; 215(3):317-29. PubMed ID: 16712893
    [Abstract] [Full Text] [Related]

  • 7. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
    Crespo NC, Delarue F, Ohkanda J, Carrico D, Hamilton AD, Sebti SM.
    Cell Death Differ; 2002 Jul 15; 9(7):702-9. PubMed ID: 12058275
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE.
    Cancer Res; 2001 Dec 15; 61(24):8758-68. PubMed ID: 11751396
    [Abstract] [Full Text] [Related]

  • 9. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1998 Mar 15; 16(11):1467-73. PubMed ID: 9525745
    [Abstract] [Full Text] [Related]

  • 10. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase.
    Wherlock M, Gampel A, Futter C, Mellor H.
    J Cell Sci; 2004 Jul 01; 117(Pt 15):3221-31. PubMed ID: 15226397
    [Abstract] [Full Text] [Related]

  • 11. Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells.
    Mazières J, Tillement V, Allal C, Clanet C, Bobin L, Chen Z, Sebti SM, Favre G, Pradines A.
    Exp Cell Res; 2005 Apr 01; 304(2):354-64. PubMed ID: 15748883
    [Abstract] [Full Text] [Related]

  • 12. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors.
    Liu Ax, Du W, Liu JP, Jessell TM, Prendergast GC.
    Mol Cell Biol; 2000 Aug 01; 20(16):6105-13. PubMed ID: 10913192
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM.
    Oncogene; 1997 Sep 01; 15(11):1283-8. PubMed ID: 9315095
    [Abstract] [Full Text] [Related]

  • 14. Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells.
    Morgan MA, Sebil T, Aydilek E, Peest D, Ganser A, Reuter CW.
    Br J Haematol; 2005 Sep 01; 130(6):912-25. PubMed ID: 16156861
    [Abstract] [Full Text] [Related]

  • 15. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors.
    Zeng PY, Rane N, Du W, Chintapalli J, Prendergast GC.
    Oncogene; 2003 Feb 27; 22(8):1124-34. PubMed ID: 12606940
    [Abstract] [Full Text] [Related]

  • 16. Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors.
    Liu A, Prendergast GC.
    FEBS Lett; 2000 Sep 22; 481(3):205-8. PubMed ID: 11007964
    [Abstract] [Full Text] [Related]

  • 17. Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
    Delarue FL, Adnane J, Joshi B, Blaskovich MA, Wang DA, Hawker J, Bizouarn F, Ohkanda J, Zhu K, Hamilton AD, Chellappan S, Sebti SM.
    Oncogene; 2007 Feb 01; 26(5):633-40. PubMed ID: 16909123
    [Abstract] [Full Text] [Related]

  • 18. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS, Ahmed MM.
    Oncogene; 2002 Nov 07; 21(51):7883-90. PubMed ID: 12420225
    [Abstract] [Full Text] [Related]

  • 19. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF, Prendergast GC.
    Oncogene; 1998 Sep 17; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [Abstract] [Full Text] [Related]

  • 20. Cyclin B1 is a critical target of RhoB in the cell suicide program triggered by farnesyl transferase inhibition.
    Kamasani U, Huang M, Duhadaway JB, Prochownik EV, Donover PS, Prendergast GC.
    Cancer Res; 2004 Nov 15; 64(22):8389-96. PubMed ID: 15548709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.